Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Testicular Neoplasms | 18 | 2024 | 64 | 4.620 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 13 | 2024 | 36 | 3.340 |
Why?
|
| Seminoma | 4 | 2018 | 8 | 1.900 |
Why?
|
| Prostatic Neoplasms | 7 | 2021 | 394 | 0.960 |
Why?
|
| Adenocarcinoma | 5 | 2020 | 397 | 0.900 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 314 | 0.720 |
Why?
|
| Neoplasms | 3 | 2022 | 1249 | 0.680 |
Why?
|
| Neoplastic Stem Cells | 3 | 2016 | 103 | 0.640 |
Why?
|
| Glypicans | 1 | 2018 | 1 | 0.630 |
Why?
|
| Neoplasm Metastasis | 6 | 2022 | 236 | 0.620 |
Why?
|
| Endodermal Sinus Tumor | 2 | 2018 | 2 | 0.610 |
Why?
|
| Tissue Extracts | 1 | 2017 | 13 | 0.590 |
Why?
|
| Up-Regulation | 1 | 2018 | 453 | 0.550 |
Why?
|
| Immunotherapy | 1 | 2017 | 240 | 0.500 |
Why?
|
| Male | 29 | 2024 | 25399 | 0.500 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2020 | 613 | 0.490 |
Why?
|
| CA-125 Antigen | 1 | 2014 | 17 | 0.490 |
Why?
|
| Retrospective Studies | 12 | 2022 | 6134 | 0.450 |
Why?
|
| Middle Aged | 21 | 2024 | 12206 | 0.450 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 208 | 0.430 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 194 | 0.420 |
Why?
|
| Lymph Node Excision | 7 | 2020 | 137 | 0.410 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 294 | 0.400 |
Why?
|
| Immunohistochemistry | 6 | 2024 | 978 | 0.390 |
Why?
|
| Carcinoma, Ductal | 2 | 2021 | 9 | 0.370 |
Why?
|
| Aged | 12 | 2024 | 9405 | 0.370 |
Why?
|
| Viscera | 1 | 2010 | 21 | 0.370 |
Why?
|
| Humans | 31 | 2024 | 50208 | 0.360 |
Why?
|
| Adult | 18 | 2024 | 13324 | 0.350 |
Why?
|
| Mutation | 3 | 2022 | 1294 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 1161 | 0.310 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 123 | 0.300 |
Why?
|
| Young Adult | 8 | 2024 | 3981 | 0.290 |
Why?
|
| Prostate-Specific Antigen | 4 | 2020 | 47 | 0.290 |
Why?
|
| Stem Cells | 2 | 2022 | 171 | 0.270 |
Why?
|
| Prognosis | 6 | 2014 | 1954 | 0.250 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2024 | 2 | 0.250 |
Why?
|
| Epithelioid Cells | 1 | 2024 | 13 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 990 | 0.240 |
Why?
|
| Lymphatic Metastasis | 5 | 2009 | 227 | 0.200 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2022 | 2 | 0.200 |
Why?
|
| Wilms Tumor | 1 | 2022 | 18 | 0.200 |
Why?
|
| Carcinoma | 2 | 2022 | 139 | 0.200 |
Why?
|
| Penile Neoplasms | 1 | 2002 | 45 | 0.200 |
Why?
|
| Adolescent | 9 | 2022 | 6390 | 0.200 |
Why?
|
| Sarcoma | 1 | 2022 | 67 | 0.190 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2014 | 14 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2002 | 509 | 0.170 |
Why?
|
| Survival Analysis | 3 | 2017 | 666 | 0.160 |
Why?
|
| Choriocarcinoma, Non-gestational | 1 | 2018 | 2 | 0.160 |
Why?
|
| Autopsy | 1 | 2018 | 47 | 0.160 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 2 | 2024 | 6 | 0.150 |
Why?
|
| Teratoma | 2 | 2009 | 26 | 0.150 |
Why?
|
| Phenotype | 2 | 2016 | 733 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2018 | 139 | 0.150 |
Why?
|
| Exome | 1 | 2016 | 46 | 0.140 |
Why?
|
| Survival Rate | 3 | 2014 | 901 | 0.140 |
Why?
|
| Cisplatin | 1 | 2018 | 278 | 0.140 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 18 | 0.130 |
Why?
|
| Disease Progression | 5 | 2011 | 831 | 0.130 |
Why?
|
| alpha-Fetoproteins | 2 | 2013 | 15 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 605 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 550 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 410 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 581 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2014 | 62 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 828 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2024 | 5155 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2020 | 996 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 40 | 0.110 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2013 | 46 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2016 | 650 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 165 | 0.110 |
Why?
|
| Glutathione Transferase | 1 | 2013 | 174 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 3154 | 0.100 |
Why?
|
| Bone Neoplasms | 2 | 2011 | 183 | 0.100 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2011 | 6 | 0.100 |
Why?
|
| Quinazolines | 1 | 2011 | 33 | 0.090 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2010 | 2 | 0.090 |
Why?
|
| Sialoglycoproteins | 1 | 2010 | 12 | 0.090 |
Why?
|
| Antigens, Surface | 1 | 2010 | 54 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 36 | 0.090 |
Why?
|
| Retroperitoneal Space | 5 | 2007 | 32 | 0.090 |
Why?
|
| Orchiectomy | 3 | 2022 | 41 | 0.090 |
Why?
|
| Proteoglycans | 1 | 2010 | 80 | 0.090 |
Why?
|
| Disease-Free Survival | 5 | 2011 | 454 | 0.090 |
Why?
|
| Hemangiosarcoma | 1 | 2010 | 16 | 0.090 |
Why?
|
| Piperazines | 1 | 2011 | 118 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 19 | 0.090 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2009 | 20 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2010 | 697 | 0.080 |
Why?
|
| Proteins | 1 | 2010 | 345 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 1186 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2006 | 263 | 0.060 |
Why?
|
| Child | 1 | 2016 | 6851 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 266 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2007 | 636 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2002 | 99 | 0.050 |
Why?
|
| Thorax | 1 | 2020 | 16 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 863 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2020 | 81 | 0.040 |
Why?
|
| Prostate | 1 | 2020 | 117 | 0.040 |
Why?
|
| Risk | 2 | 2007 | 324 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 1262 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2009 | 738 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2010 | 13 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 377 | 0.020 |
Why?
|
| Leiomyosarcoma | 1 | 2010 | 23 | 0.020 |
Why?
|
| Recurrence | 1 | 2009 | 662 | 0.020 |
Why?
|
| Forecasting | 1 | 2007 | 150 | 0.020 |
Why?
|
| Pathology, Surgical | 1 | 2006 | 18 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 238 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 164 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 288 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 328 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 2922 | 0.010 |
Why?
|
| Female | 1 | 2020 | 26635 | 0.010 |
Why?
|